NRx Pharmaceuticals, Inc. (NRXP): Price and Financial Metrics
GET POWR RATINGS... FREE!
NRXP Stock Price Chart Interactive Chart >
NRXP Price/Volume Stats
| Current price | $1.23 | 52-week high | $3.54 |
| Prev. close | $1.25 | 52-week low | $0.49 |
| Day low | $1.18 | Volume | 246,865 |
| Day high | $1.26 | Avg. volume | 338,706 |
| 50-day MA | $1.22 | Dividend yield | N/A |
| 200-day MA | $0.97 | Market Cap | 83.26M |
NRx Pharmaceuticals, Inc. (NRXP) Company Bio
NRX Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company specializes in researching investigational medicines and is engaged in the development of medicines and vaccines for Covid-19, other respiratory conditions, suicidal depression, and PTSD.
Latest NRXP News From Around the Web
Below are the latest news stories about NRX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NRXP as an investment opportunity.
NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101. |
NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare ConferenceNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates ("6th Annual NIF"). The forum takes place Sunday, January 8, 2023, as part of the activities surrounding the annual J.P. Morgan |
NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site ContractedNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that its first clinical trial site has been contracted (with others expected in near future) and that first dosing of patients is expected in early 2023. This Phase 3 clinical trial of NRX-101 is for the treatment of Severe Bipolar Depression with Acute Suicidal Ideation and Behavior ("SBD-ASIB"), a lethal condition that currently takes the lives of thousan |
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement AgreementsRelief Therapeutics Holding SA / Key word(s): Legal Matter Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements 20-Dec-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. |
Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement AgreementsRelief Therapeutics Holding SA / Key word(s): Legal Matter Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements 20-Dec-2022 / 07:00 CET/C… |
NRXP Price Returns
| 1-mo | 11.82% |
| 3-mo | 51.85% |
| 6-mo | 55.11% |
| 1-year | -56.99% |
| 3-year | N/A |
| 5-year | -87.32% |
| YTD | 10.81% |
| 2022 | -76.78% |
| 2021 | -80.41% |
| 2020 | 130.19% |
| 2019 | 3.92% |
| 2018 | N/A |
Loading social stream, please wait...